论文部分内容阅读
目的:为提高患者激活自身免疫细胞抗肿瘤活性,且杀灭胸水癌细胞的作用,达到减少恶性胸水及减轻患者痛苦的目的。方法:确诊为恶性胸水的患者共66例,随机分成两组,即复方苦参注射液、顺铂联合用药组与顺铂组,每组33例。两组患者在胸腔穿刺抽液后,分别注入不同药物处理,比较两种处理方法对消胸水灌注药物次数有无差别。结果:两组患者消胸水用药灌注次数及不良反应有差别(P<0.05)。复方苦参注射液、顺铂联合用药灌注组优于单纯顺铂灌注组。结论:复方苦参注射液、顺铂联合用药对激活免疫细胞抗肿瘤活性、杀灭癌细胞,促进胸膜粘连,既达到减少恶性胸水,又有提高患者抗病能力的作用。
OBJECTIVE: To improve the anti-tumor activity of autoimmune immune cells in patients and to kill pleural effusion cancer cells, so as to reduce the risk of malignant pleural effusion and reduce the suffering of patients. Methods: A total of 66 patients with malignant pleural effusion were randomly divided into two groups: compound Kushen injection, cisplatin combination group and cisplatin group, 33 cases in each group. After the thoracentesis, the two groups of patients were injected with different drugs, and there was no difference in the number of times that the two treatments were used to inject the drugs. RESULTS: There were differences in the number of infusions and adverse reactions between the two groups (P<0.05). Compound Kushen injection and cisplatin combined perfusion group were superior to single cisplatin perfusion group. Conclusion: Compound Kushen Injection and Cisplatin combination therapy can activate anti-tumor activity of immune cells, kill cancer cells and promote pleural adhesions, which can not only reduce malignant pleural effusion, but also increase the resistance of patients.